EGFR and non-small cell lung carcinoma: A subsequent confirmatory phase III study that compared erlotinib plus bevacizumab, with erlotinib alone, in patients with untreated NSCLC that were positive for activating EGFR mutations (NEJ 026) showed that the median PFS, as determined by independent review, was 16.9 months compared to 13.3 months (HR = 0.605, p = 0.016), respectively [12] (Table 1).